Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00066599 · ClinicalTrials.gov registry record · Phase 2

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase

NCT00066599: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00066599 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00066599, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who have neutropenia after receiving chemotherapy for leukemia, lymphoma, or aplastic anemia or in preparation for bone marrow or stem cell transplantation.

Interventions

  • DRUG voriconazole

Trial Details

FieldValue
Start Date 2003-06
Est. Completion 2004-06
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00066599 record still lists

NCT00066599 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which voriconazole is the first listed.

NCT00066599 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00066599 about?

NCT00066599 is a clinical study titled "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy". RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who have neutropenia after receiving chemotherapy for leukemia, lymphoma,...

What is the current status of trial NCT00066599?

This trial is currently completed. It is a Phase 2 study. The study started on 2003-06. Estimated completion is 2004-06.

What interventions are being tested in trial NCT00066599?

The interventions under investigation include: voriconazole (DRUG).

Who is sponsoring clinical trial NCT00066599?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00066599, the US trial registry maintained by the National Library of Medicine. NCT00066599 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.